Stakeholders ask FDA to be more flexible on rescinding breakthrough drugs designations
Regulatory NewsFerdous Al-Faruque
Clinical TrialsComplianceNorth AmericaPharmaceuticalsProduct LifecycleRegulatory Intelligence/PolicyResearch, Design and Development